NewsSource: EClinCloud official website archive

EClinCloud Expands Collaboration with Kangzhe Biotech to Help Improve Clinical Trial Efficiency with an Integrated Cloud Platform

3 min readEClinCloud Editorial Team
Archived article cover: EClinCloud expands collaboration with Kangzhe Biotech to help improve clinical trial efficiency with an integrated cloud platform

Recently, EClinCloud signed a strategic cooperation agreement with Shenzhen Kangzhe Biotechnology Co., Ltd. (hereinafter referred to as "Kangzhe Biotech"). The two parties further expanded their collaboration, confirming that Kangzhe Biotech will adopt EClinCloud's EDC and RTSM systems.

Previously, Kangzhe Biotech had long used EClinCloud's eTMF system, eCOA system, and scale management services in clinical studies, and this collaboration marks deeper integration between the two parties in the field of clinical trials.

EClinCloud EDC goes beyond traditional EDC systems and better aligns with future trends; combining the strengths of multiple international EDC systems with the usage habits of users in China, it will help Kangzhe Biotech achieve digital and intelligent clinical trial data capture, remote data review, and transparent data standards.

The EClinCloud RTSM system represents an advanced, web-based randomization and drug supply management platform for multi-center clinical trials. Used to efficiently manage large-scale, multi-center clinical trials with multiple parallel protocol versions, it can help investigators control trial workflows more precisely, ensure smooth trial conduct, and improve the standardization of drug management.

Notably, as the scope of collaboration expands, the "integrated" advantage across systems becomes even more pronounced, which will greatly help Kangzhe Bio improve data management efficiency and shorten R&D cycles. EClinCloud's integrated, interconnected platform brings together previously standalone systems, reducing duplicate data entry and cumbersome document management, while enabling data interoperability across systems to maximize the value of data.

Yin Yuanyuan, Head of Clinical Development / Head of Medical at China Medical System (CMS) Group, said:

"Expanding our collaboration with EClinCloud has greatly strengthened our confidence in optimizing clinical process management and improving data quality. Kangzhe Bio places great importance on informatization, digitalization, and intelligent technologies in clinical research. With EClinCloud's professional support, we believe we can greatly improve clinical operations efficiency, accelerate the drug launch process, and benefit patients broadly."

Dr. Qin Long, Founder and CEO of EClinCloud, said:

"Leveraging EClinCloud's interconnected, integrated cloud platform, we will provide Kangzhe Bio with more reliable digital solutions and further improve clinical data quality and overall project quality, using efficient, high-quality clinical operations to drive more R&D breakthroughs and benefit more patients."

 

About EClinCloud

With "bringing effective treatments to patients through technological innovation" as its mission, it is a technology company focused on clinical research and development, providing an integrated, interconnected, unified clinical trial cloud platform and clinical trial endpoint assessment technologies across different therapeutic areas, combining cutting-edge technology with life data to build a globally leading "patient-centric" clinical evidence support SaaS cloud platform to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs/devices, and benefit countless patients

About Kangzhe Biopharma & China Medical System (CMS)

CMS Biopharma is a subsidiary of China Medical System (867.HK). China Medical System is an open, platform-based enterprise linking pharmaceutical innovation and commercialization while managing the full product lifecycle. It focuses on first-in-class (FIC) and best-in-class (BIC) innovative products, efficiently advancing their clinical research, development, and commercialization, and enabling the continuous translation of scientific research achievements into clinical practice to benefit patients. Focusing on specialty areas, China Medical System has proven commercialization capabilities, broad channel coverage, and expert resources across multiple disease areas, with its core marketed products having achieved leading academic and market positions. China Medical System continues to deepen its development around its advantageous specialty areas to consolidate the competitiveness of its cardiovascular/cerebrovascular and gastroenterology businesses, while operating its dermatology and medical aesthetics as well as ophthalmology businesses independently to cultivate major leaders in niche specialty segments and improve specialty scale efficiency.

 

 

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.